Zymeworks Inc. filed its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission on October 26, 2026, covering the fiscal year ended December 31, 2025.

Key Highlights

  • Exchange and ticker: Common stock ($0.00001 par value per share) is listed on The Nasdaq Stock Market LLC under the symbol ZYME.
  • Shares outstanding: As of February 26, 2026, the registrant reported 73,749,607 shares of common stock outstanding.
  • Non-affiliate market cap: The aggregate market value of voting and non-voting common shares held by non-affiliates was approximately $649.5 million, based on the closing price on the last business day of the second fiscal quarter.
  • Filer classification: The registrant indicated it is a non-accelerated filer and a smaller reporting company, and it is not an emerging growth company.
  • Internal control attestation: The registrant indicated it has not filed a report and attestation on management's assessment of internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act by its registered public accounting firm.
  • Shell company status: The registrant indicated it is not a shell company as defined under Rule 12b-2 of the Securities Exchange Act of 1934.

Zymeworks Annual Report: Key Filing Details and Company Profile

Zymeworks Inc., incorporated in Delaware (I.R.S. Employer Identification Number 88-3099146), filed its Form 10-K for the fiscal year ended December 31, 2025, with principal executive offices located at 108 Patriot Drive, Suite A, Middletown, Delaware 19709. The filing is registered under Commission file number 001-41535. The company's common stock trades on NASDAQ:ZYME.

According to the filing, the registrant's business strategy centers on milestone and royalty revenue from existing and potential new partnerships, as well as the development of therapeutic platforms and antibody engineering expertise. The filing notes that the company expects future revenue to arise from strategic collaborations and the compounding of long-term value through royalty-generating assets, though it cautions that all such statements are forward-looking and subject to material uncertainties described in the "Risk Factors" and "Management's Discussion and Analysis" sections of the report.

The filing confirmed that the registrant submitted all required Interactive Data Files electronically pursuant to Rule 405 of Regulation S-T during the preceding 12 months, and that it has been subject to SEC reporting requirements for more than 90 days. The registrant also indicated that its financial statements do not reflect a correction of an error to previously issued financial statements, and that no recovery analysis of incentive-based compensation was required.

What Was Disclosed

Zymeworks Inc. filed its fiscal year 2025 Annual Report on Form 10-K, disclosing share count, non-affiliate market capitalization of approximately $649.5 million, filer classifications, and general information about its partnership-focused business strategy and forward-looking assumptions.